EDEN
PRAIRIE, Minn., Sept. 22,
2022 /PRNewswire/ -- NeuroOne Medical Technologies
Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical
technology company focused on improving surgical care options and
outcomes for patients suffering from neurological disorders today
announced that, effective September 20,
2022, the Compensation Committee of the Board of Directors
approved two equity awards under the NeuroOne Medical Technologies
Corporation 2021 Inducement Plan (the "Inducement Plan"), as a
material inducement to the individuals entering into employment
with the Company. The equity awards were approved in accordance
with Nasdaq Listing Rule 5635(c)(4), which also requires a public
announcement of awards that are not made under a stockholder
approved equity plan.
In connection with entering into employment with NeuroOne, the
individuals, who were not previously employees or directors
of NeuroOne, each received an option to purchase 1,000 shares
of the Company's common stock. The option awards have an exercise
price of $1.97 per share, the closing price of NeuroOne's
common stock on September 20, 2022, the date of the grant. The
options have a ten-year term and vest as to 25% on the first
anniversary of each new hire's start date, with the remaining
shares vesting in equal monthly installments on the last day of
each month over the next thirty-six (36) months, provided the new
hire's employment is continuing on each such date.
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental
stage company committed to providing minimally invasive and
hi-definition solutions for EEG recording, brain stimulation and
ablation solutions for patients suffering from epilepsy,
Parkinson's disease, dystonia, essential tremors, chronic pain due
to failed back surgeries and other related neurological disorders
that may improve patient outcomes and reduce procedural costs. For
more information, visit https://www.n1mtc.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/neuroone-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301630765.html
SOURCE NeuroOne Medical Technologies Corporation